PMS36 Economic Analysis of Etanercept in Rheumatoid Arthritis from a Public perspective in Colombia  by Fernandes, R.A. et al.
OBJECTIVES: Anti-tumour necrosis factor inhibitor (anti-TNF) therapy has been
widely and successfully used in patients with rheumatoid arthritis (RA). However,
about 30% of these patients have an inadequate response to these medicines.
Abatacept has shown significant clinical and functional benefits in patients who
have inadequate response to anti-TNF therapy. The aim of this analysis is to ex-
amine the cost-effectiveness of abatacept after the failure of a first anti-TNF.
METHODS: A patient simulation model was constructed using clinical data from
the (abatacept) ATTAIN trial and the British Society for Rheumatology Biologics
Register (BSRBR). The time horizon of this model was lifetime. Clinical effective-
ness was evaluated by changes in Health Assessment Questionnaire (HAQ) score
from baseline up to 12 months. Patients discontinued treatment due to a lack of
efficacy or adverse events. After treatment discontinuation, patients received sup-
portive care, regardless of treatment group. Utilities were obtained by mapping
HAQ to EQ-5D. Cost inputs included drug and administration, monitoring, medical
costs associated with HAQ level, and joint replacement costs obtained from pub-
lished literature and inflated to 2009 British pounds. RESULTS: Abatacept was es-
timated to yield 1.06 additional quality-adjusted life years (QALYs) per patient (3.28
vs. 2.22) over a lifetime, compared to conventional DMARDs. The total lifetime
costs associated with abatacept were £46,522 and total costs for conventional
DMARDs were £17,025, resulting in an incremental cost-effectiveness ratio (ICER) of
£27,936 per QALY gained. Probabilistic and univariate sensitivity analyses con-
firmed the robustness of our findings. CONCLUSIONS:Abatacept is a cost-effective
treatment option for patients with RA after the failure of a first anti-TNF in the UK.
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OBJECTIVES: Rheumatoid Arthrtis (RA) leads to significant impact on management
costs and patient’s quality of life. In Venezuela, annual per capita cost for RA
management increased from 698USD in 1997 to 3494USD in 2002. Biologic treat-
ment after disease-modifying antirheumatic drugs fail is an alternative, but their
high cost represents a challenge for decision makers. This study aims to perform
cost-effectiveness and cost-utility analysis of biologic alternatives for moderate to
severe RA in Venezuela. METHODS: An economic analysis was developed through
a decision-tree model to simulate RA evolution after treatment with etanercept
(basecase treatment), adalimumab, infliximab, tocilizumab or rituximab as first-
line therapies and their associated costs over a 12-month time horizon. Therapy
continuation or switch was evaluated at week 24. Effectiveness measures were
ACR70 response and quality adjusted life years (QALYs) gained. Direct medical
costs included biologics, concomitant drugs, medical follow-up and adverse events
management. Clinical response was extracted from published literature, while
costs were collected from Venezuelan public official databases. Probabilistic sen-
sitivity analyses were performed through Monte Carlo Simulation second-order
approach. RESULTS: In base case analysis estimated effectiveness resulted in
[ACR70,QALY]: etanercept [31.3%,0.79]; adalimumab [18.1%,0.77]; infliximab
[12.8%,0.73]; tocilizumab [21.1%,0.77] and rituximab [11.9%, 0.75]. Expected mean
costs per patient were 13,588USD, 15,451USD; 15,950USD; 18,705USD and
14,350USD, respectively. In cost-effectiveness and cost-utility analysis, etanercept
was the least costly and the most effective alternative being cost-saving in all
comparisons: 5117USD less than tocilizumab (most costly alternative); 19.4% more
patients met ACR70 response regarding rituximab (the least effective alternatives);
incremental utility reached0.0576 QALYs versus infliximab. Acceptability curves
showed that etanercept regardless willingness to pay would be the most cost-
effective biologic. CONCLUSIONS: Due to its lower costs and favorable effective-
ness profile, etanercept is dominant regarding ACR70 response and QALYs gained
over other biologic treatments in the management of RA at Venezuelan public
health care system.
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OBJECTIVES: Osteoporosis (OP) and fragility fractures (FF) significantly affect both
mortality and health-related-quality-of-life, causing high costs. We aimed to de-
termine the cost and the effectiveness of three different bisphosphonates (BP) in
Mexico. METHODS: A six health-state life-time Markov microsimulation model
was adapted to compare intravenously (IV) ibandronate 3mg injection every 3
months (IBD), oral weekly (OW) alendronate 70mg (ALD) and OW risedronate 35mg
(RSD), under the perspective of the public health care system in Mexico. Target
population consists of postmenopausal (PW) women over 50 years with or without
prior fracture. Only direct costs were accounted for and these included drug acqui-
sition and acute medical attention of FF. All costs are expressed in 2009 United
States dollars (USD). Unit cost and antifracture efficacy was derived from published
literature. Outcomes measures were the type and frequency of FF avoided with
each agent compared with no treatment and quality-adjusted life years (QALY).
Cost and efficacy were calculated taking into account persistence and compliance
data. RESULTS: The avoided fractures rate was higher with IV IBD (644 per 10,000
patients Vs. 205 and 203 with ALD and RSD, respectively). When compared with
OW BP, IV IBD reduced the total FF frequency in about 10%. Hence, the use of IV IBD
resulted in a gain of 37 QALY per every 1,000 patients. The incremental cost per
QALY gained with IV IBD ranged from 9898 USD (vs. ALD) to 15,047 USD (vs. RSD).
The gross domestic product per capita in Mexico during 2009 was estimated at 8337
USD. Results were robust to variation in all parameters. CONCLUSIONS: By reduc-
ing significantly the number of doses needed per year, IV IBD improves adherence
and decrease the expected frequency of FF in comparison with OW BF. These
results suggest that IV IBD is a cost-effective intervention for PM OP in Mexico.
PMS34
COST-EFFECTIVENESS ANALYSIS OF BIO- HYALURONIC ACID (HA) IN PATIENTS
WITH KNEE OSTEOARTHRITIS IN MEXICO
Aguirre A1, Bierschwale H1, Espinosa F1, Michel M2, Aguilera J3, Esquivel R4, Oliva C4,
Sierra M5, Martínez M6
1UCB de Mexico, S.A. de C.V., Mexico, D.F., Mexico, 2ISSSTE, 20 de Noviembre, Mexico, D.F.,
Mexico, 3Instituto Nacional de Rehabilitación, Mexico, D.F., Mexico, 4IMSS, Lomas Verdes, Estado
de México, Naucalpan, Mexico, 5PEMEX Norte, Mexico, D.F., Mexico, 6Hospital General Balbuena,
Mexico, D.F., Mexico
BACKGROUND: Osteoarthritis (OA) is the most common rheumatic disease in the
world and one of the main causes of joint pain and disability of the adult popula-
tion; it therefore represents an important use of medical resources for the institu-
tions and compromises the quality of life of patients. OBJECTIVES: To analyze the
cost-effectiveness of Bio-HA vs. Hilano G-F20 in patients with knee osteoarthritis.
METHODS: We conducted an economic evaluation. The alternatives to compare
were Bio-HA vs Hilano, administered three weekly injections, with follow-up eval-
uations at week 12. The perspective is the Mexican Social Security Institute (IMSS).
The economic model included the cost of drug acquisition and management of
adverse events (AE). The use of resources associated with each AE was defined
according to a Delphi Panel. The efficacy measure was the proportion of patients
with OMERACT-OARSI response, obtained from a head to head analysis (Onel E,
2008).RESULTS:The response rates for Bio-HA were 71% versus 63% for Hilano. The
knee effusions in patients treated with Bio-HA was 0.6% (MX$39) vs. Hilano 8.1%
(MX$531). The cost per patient treated for each alternative was MX$7728 and
MX$8338 for Bio-HA and Hilano, respectively. The cost per responder patient was
lower for Bio-HA than Hilano, MX $10,885 and MX $13,236, respectively. So, the
savings generated by Bio-HA are very high. If we consider the 1,000 patients for
each alternative, the savings would be MX$610,000 and this money be useful to
purchase an extra 122 cycles of treatment with Bio-HA or to be reassign for other
therapeutic areas. Considering all the above Bio-HA proved to be a dominant strat-
egy (less costly and more effective). CONCLUSIONS: The results of this pharmaco-
economic analysis suggest that the use of Bio-HA in patients with OA is a cost-
saving strategy for the institutions of public health in Mexico.
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OBJECTIVES: To evaluate the cost-effectiveness of denosumab compared to sup-
portive care (no active osteoporosis treatment), alendronate, ibandronate, risend-
ronate and strontium ranelate for the treatment of women with post-menopausal
osteoporosis (PMO) in Greece.METHODS:An 8-state, 6-month cycle Markov cohort
model was developed in order to estimate costs and effects, i.e. reductions in
fracture occurrence, of denosumab vs. comparators for a 5year period, from a
third-party payer perspective (Euros, 2011). The model was populated according to
the characteristics of the FREEDOM clinical trial population (mean age: 72.3, prev-
alence of vertebral fracture: 23.6%, femoral neck T-score2.5), that also provided
the data on efficacy of denosumab. Data on efficacy (relative risk of fractures) for
the comparators were taken from a published meta-analysis. The model took into
account treatment persistence across all comparators, as well as a 2year residual
effect of treatment after discontinuation. RESULTS: The base-case analysis
showed that the incremental cost per QALY gained with denosumab was €18,813,
€24,784, €13,727, €18,436 and €11,114 versus no treatment, alendronate, ibandro-
nate, risendronate and strontium ranelate, respectively. The probabilistic sensitiv-
ity analysis demonstrated that denosumab was cost-effective in an implicit €30,000
threshold for 81.6% of the iterations versus no treatment and risendronate, 63.4%
versus no treatment and alendronate and 88.2% versus no treatment and ibandro-
nate. Univariate sensitivity analyses showed that changes in persistence rates,
baseline age and T-score where the factors with the most significant influence in
the results. CONCLUSIONS: In a disease that entails a significant morbidity and
socioeconomic burden, denosumab seems to be a cost-effective alternative to es-
tablished treatment regimens for osteoporosis in Greece.
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OBJECTIVES: Rheumatoid Arthrtis (RA) leads to significant impact on management
costs and patient’s quality of life if no therapeutic measure is adopted and repre-
sents one of five most common incapacity causes in women aged 15-44 years, in
Colombia. Biologic treatment after disease-modifying antirheumatic drugs fail is
an alternative, but their high cost represents a challenge for decision makers. This
study aims to perform cost-effectiveness and cost-utility analysis of biologic alter-
natives for moderate to severe RA in Colombia, from a public perspective.
METHODS: An economic analysis was developed through a decision-tree model to
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simulate RA evolution after treatment with etanercept (basecase treatment), ada-
limumab or infliximab as first-line therapies and their associated costs over a
12-month time horizon. Therapy continuation or switch was evaluated at week 24.
Effectiveness measures were ACR70 response and quality adjusted life years
(QALYs) gained. Direct medical costs included biologics, concomitant drugs, med-
ical follow-up and adverse events management. Clinical response was extracted
from published literature, while costs were collected from Colombian public offi-
cial databases. Probabilistic sensitivity analyses were performed through Monte
Carlo Simulation second-order approach. RESULTS: In base case analysis esti-
mated effectiveness resulted in [ACR70, QALY]: etanercept [31.3%, 0.79]; adali-
mumab [18.1%, 0.77] and infliximab [12.8%, 0.73]. Expected mean costs per patient
were 23,065USD, 24,869USD and 25,853USD, respectively. In cost-effectiveness and
cost-utility analysis, etanercept was the less costly and the most effective alterna-
tive being cost-saving in all comparisons: 2789USD less than infliximab(most costly
alternative); 18.5% more patients met ACR70 response regarding infliximab(the
least effective alternatives); incremental utility reached -0.0576 versus infliximab.
Acceptability curves showed that etanercept regardless willingness to pay would
be the most cost-effective biologic. CONCLUSIONS: Due to its lower costs and
favorable effectiveness profile, etanercept is dominant regarding ACR70 response
and QALYs gained over other biologic treatments in the management of RA at
Colombian public health care system.
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OBJECTIVES: Oral glucosamine formulations are frequently used as a food supple-
ment for joint maintenance, with little supportive evidence. However, Glusartel, a
formulation of glucosamine (produced by Rottapharm), has been shown to in-
crease oral bioavailability and has been studied in over 7,000 patients, showing a
significant improvement in joint space narrowing and knee replacement. The cost-
effectiveness of the new product was studied compared to both standard of care
and other glucosamine products. METHODS: A four state (with death as a sink
state) Markov model was constructed to investigate disease progression, patient
utility (mapped from the Western Ontario and McMaster Universities Arthritis
Index (WOMAC)) and cost. Efficacy was taken from two pivotal trials, while costs
were taken from standard sources including NHS Reference Costs, PSSRU, and the
British National Formulary. All costs were inflated to financial year 2009/2010, with
the perspective taken that of NHS Scotland. RESULTS: Using a 50 year (lifetime)
time horizon, with patients beginning treatment at age 62 (as seen in the clinical
trials), patients treated with Glusartel are estimated to cost £1799 more than those
treated with standard management (£6443 vs. £4645), but gain an additional 0.15 (2
d.p.) QALYs (9.45 vs. 9.31), generating an ICER of £12,402. Compared with currently
used glucosamine treatment, even conservatively assuming equal efficacy, Glusar-
tel produces a cost saving of £700, and is dominant in outcomes when the assump-
tion around treatment efficacy is relaxed. The model is sensitive to the time hori-
zon, utility in mild/moderate arthritis and data source for costs, with the main
driver being the efficacy of Glusartel in delaying severe arthritis. CONCLUSIONS:
From the perspective of NHS Scotland Glusartel is highly cost-effective compared
to standard of care, and cost saving compared to other glucosamine products. By
revising existing prescribing patterns, NHS Scotland could both improve patient
outcomes, and realise cost savings.
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OBJECTIVES: To review relevant Rheumatoid Arthritis (RA) economic models for
biologics; and identify potential model limitations. METHODS: Search targeted
economic evaluations of RA biologics since 2000 using Medline, EMBASE, and Co-
chrane databases. Articles were subjected to a two level review process before data
abstraction. RESULTS: Twenty-six economic evaluations were published assessing
costs and outcomes associated with RA biologics. Most models used a payer per-
spective. Two methotrexate (MTX)-naïve patient models were cost utility analyses
(CUA); one was a patient simulation model and one a decision analytic model. Of
seventeen models for disease modifying anti-rheumatic drug (DMARD)/MTX fail-
ure populations, sixteen were CUAs and one was a cost-effectiveness (CE) model
based on cost/ACR improvement achieved; model structures included patient level
simulation, Markov, and decision analytic models. Of seven models identified for
anti-TNF inhibitor failure populations, five were CUAs and two were CE models
where CE was defined by both cost/remission and cost of achieving low disease
activity (Disease Activity Score (DAS)28 3.2); six models employed a simulation
structure and one a Markov structure. Results varied widely across studies due to
heterogeneity in the time horizon, perspectives, year of costs and comparators.
Model Incremental cost effectiveness ratios (ICERs) ranged from $4,849 (2007$)
$47,157 (2007$) per QALY for MTX-naïve, $14,518 (1998$) $498,420 (2005$) per
QALY for DMARD/MTX failure, and $12,869 (2006$)$76,363 (2008$) per QALY for
TNF-failure. Key limitations included limited availability of treatment data over
long time horizons, and use of Health Assessment Questionnaire (HAQ) as primary
outcome and as determinant of utility. CONCLUSIONS: We recommend future
modeling efforts evaluate the use of direct utilities versus mapping; advantages of
CUA versus CE and simulation approach using patient level data; benefits of longer
time horizon; and inclusion of both health related quality of life assessment such
as HAQ and disease activity such as DAS-28 as model inputs.
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OBJECTIVES: Half of patients with systemic juvenile idiopathic arthritis (sJIA) will
eventually fail to non-steroidal anti-inflammatory drugs (NSAIDs) or corticoste-
roids. Tocilizumab (TCZ) is indicated for patients with refractory sJIA. We aimed to
determine the cost and the effectiveness of adding TCZ to conventional treatment
for sJIA in Mexico. METHODS: We designed two decision models to compare TCZ
versus placebo. In each model, two time horizons were analyzed: 12 weeks and one
year. Target population consists of patients (2-19 years) with active sJIA and inad-
equate response to NSAIDs and corticosteroids. The dosing scheme for TCZ was
based on body weight: 8 mg/kg for patients 30 kg and 12 mg/kg for patients 30
kg. The analysis was performed under the perspective of the public health care
system in Mexico. Tocilizumab acquisition cost, infusion fees and standard man-
agement of sJIA according to level of response were evaluated. Efficacy was defined
in terms of the American College of Rheumatology Pediatric response criteria. Re-
source use and unit costs were gathered from local sources; efficacy was derived
from two phase-3 clinical trials; increase in mortality and utility scores associated
with level of response was based on literature. All costs are expressed in 2011 euros
(€). RESULTS: A markedly higher proportion of patients achieved an ACRPedi70
response with TCZ in both children with the possibility of maintaining methotrex-
ate (71% vs. 8%) and in those without that alternative (75% vs. 13%). The incremen-
tal cost per achieving an ACRPedi70 response was around 2400€ in both models.
During base-case, the incremental cost per Quality-Adjusted Life Year (QALY)
gained with TCZ ranged from 10,636€ to 10,681€. The gross domestic product per
capita in Mexico during 2010 was estimated at 7048€. Results were robust to vari-
ation in all parameters. CONCLUSIONS: TCZ is a cost-effective option to treat sJIA
in Mexico.
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OBJECTIVES: Rheumatoid Arthritis (RA) leads to significant impact on manage-
ment costs and patient’s quality of life. In Brazil, costs associated to RA patient’s
care are 6.6-fold higher than general population, with greater resources consump-
tion. Biologic treatment after two disease-modifying antirheumatic drugs fail is an
alternative, but their high cost represents a challenge for decision makers. Cur-
rently, adalimumab, etanercept and infliximab are provided by the Brazilian public
healthcare system. This study aims to assess the cost per responder of etanercept
versus adalimumab and infliximab, for moderate to severe rheumatoid arthritis
treatment from a public payer perspective in Brazil. METHODS: A decision-tree
model was developed to simulate RA evolution after treatment with etanercept
(basecase treatment), adalimumab or infliximab as first-line therapies and their
associated costs over a 12-month time horizon. Therapy continuation or switch
was evaluated at week 24. Effectiveness measure was ACR70 response. Direct med-
ical costs included biologics, concomitant drugs, medical follow-up and adverse
events management. Clinical response was extracted from published literature,
while costs were collected from Brazilian public official databases. Probabilistic
sensitivity analyses were performed through Monte Carlo Simulation second-order
approach. RESULTS: In basecase analysis, 31.4%, 18.2% and 12.9% patients met
ACR70 response for etanercept, adalimumab and infliximab. Annual costs per
ACR70 responder were 147,147USD, 264,097USD and 327,632USD, respectively. Et-
anercept represented the least costly per ACR70 responder and the most effective
alternative in all comparisons: 116,950USD and 180,485USD less than adalimumab
and infliximab, respectively; 13.2% and 18.5% more patients met ACR70 response
regarding adalimumab and infliximab.CONCLUSIONS: Etanercept exhibited incre-
mental clinical effectiveness at a lower cost per ACR70 responders when compared
to adalimumab and infliximab, from the Brazilian public health care system.
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OBJECTIVES: Alendronate is subsidised in Australia for patients with a prior frac-
ture or those aged 70 with a bone mineral density (BMD) T-score of -3.0. The
objective of the analysis was to assess the cost-effectiveness of broadening access
to alendronate to individuals aged  70 with BMD T–score  –2.5. METHODS: A
cost-utility analysis was constructed using a microsimulation model of a Markov
process. The comparator was ‘no alendronate’ until such time that the individual
became eligible for treatment due to a fracture or to BMD T-score reaching -3. The
microsimulation transits patients through six health states of a Markov process
with the health states defined by treatment status (not eligible, on treatment,
discontinued treatment) and fracture status (with or without history of fracture).
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